Medication for Weight Management

Product Overview

Liraglutide 6 mg/5 mL (compounded) is a glucagon-like peptide-1 (GLP-1) receptor agonist formulation supplied as a sterile, preservative-free solution in a multi-dose vial. It is prescribed as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in eligible patients. This formulation is prepared under strict sterile compounding standards at The Pharmacy Hub.

Table: Essential Information Summary

Mechanism of Action

• Mimics endogenous GLP-1 to regulate appetite, slow gastric emptying, and enhance insulin secretion.
• Promotes weight loss by reducing caloric intake and improving metabolic parameters.

Indications & Eligibility:

For adults with:

• BMI =30 kg/m² (obesity) or
• BMI =27 kg/m² (overweight) + at least one weight-related comorbidity (e.g., hypertension, prediabetes, dyslipidemia).

1. Dosing & Administration:
   • Starting dose: 0.6 mg SC once daily × 1 week.
   • Weekly escalation: Increase by 0.6 mg weekly until reaching maintenance dose (max 3.0 mg/day).
   • Administration: Subcutaneous injection in abdomen, thigh, or upper arm; rotate sites.
   • Missed dose: Skip if >12 hours late; resume next scheduled dose.
2. Contraindications:
   • Personal/family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
   • Hypersensitivity to liraglutide or excipients.
   • Do not take during pregnancy.
   • Not recommended for nursing mothers.
      
3. Warnings & Precautions:

1. Adverse Reactions:
   Most common (=5%): Nausea, diarrhea, vomiting, constipation, headache, injection-site reactions, dyspepsia.
2. Storage & Stability:
   • Unopened vials: Refrigerate at 2°C–8°C (36°F–46°F).
   • In-use vials: Store at =30°C (86°F); discard 4 weeks after first use.
   • Do not freeze or expose to light.
3. Supply:
   • 5 mL multi-dose vial (6 mg/5 mL concentration).
   • Note: Concentration differs from commercial pens (6 mg/mL).